Treatment of an Adolescent With Chronic Myeloid Leukemia and the T315I Mutation With Ponatinib

被引：21
|
作者：
Nickel, Robert Sheppard [1 ]
Daves, Marla [1 ]
Keller, Frank [1 ]
机构：
[1] Emory Univ, Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Atlanta, GA 30322 USA
来源：
PEDIATRIC BLOOD & CANCER | 2015年 / 62卷 / 11期
关键词：
IMATINIB; GROWTH; CHILDREN;
D O I：
10.1002/pbc.25551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2050 / 2051
页数：2
相关论文
共 50 条
  • [1] MONITORING T315I MUTATION IN CHRONIC MYELOID LEUKEMIA BY ARMS PCR
    Dima, D. M.
    Trifa, A. P.
    Cucuianu, A.
    Popp, R. A.
    Petrov, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 572 - 573
  • [2] Asciminib Management in Chronic Myeloid Leukemia (CML) Patients With T315I Mutation
    Kuzmina, Elena
    Lomaia, Elza
    Morozova, Elena
    Chelysheva, Ekaterina
    Shukhov, Oleg
    Petrova, Anna
    Chitanava, Tamara
    Vlasova, Yulia
    Sbityakova, Evgenia
    Makarova, Tayana
    Nemchenko, Irina
    Bykova, Anastasiya
    Gurianova, Margarita
    Julhakyan, Hunan
    Kokhno, Alina
    Turkina, Anna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S334 - S334
  • [3] Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML)
    Chomel, Jean-Claude
    Sorel, Nathalie
    Bonnet, Marie-Laure
    Bertrand, Angelina
    Brizard, Francoise
    Saulnier, Pierre-Jean
    Roy, Lydia
    Guilhot, Francois
    Turhan, Ali G.
    LEUKEMIA RESEARCH, 2009, 33 (04) : 551 - 555
  • [4] METABOLIC CHARACTERISTICS OF IMATINIB RESISTANT CHRONIC MYELOID LEUKEMIA WITH T315I MUTATION
    Heo, J. Y.
    Han, J.
    Ryu, M. J.
    Jang, Y.
    Kim, S. J.
    Kim, J.
    Lee, M. J.
    Kweon, G. R.
    HAEMATOLOGICA, 2015, 100 : 432 - 432
  • [5] The Clinical Characteristics and Efficacy of Chronic Myeloid Leukemia Patients with T315I Mutation
    Chen Chen
    Na Xu
    Wu WanEr
    Liu Liang
    Xuan Zhou
    Huang JiXian
    Yin Changxin
    Rui Cao
    Liu, Qifa
    Liu Xiaoli
    BLOOD, 2018, 132
  • [6] Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era
    Haddad, Fadi G. G.
    Sasaki, Koji
    Bidikian, Aram
    Issa, Ghayas C. C.
    Kadia, Tapan
    Jain, Nitin
    Alvarado, Yesid
    Short, Nicholas J. J.
    Pemmaraju, Naveen
    Loghavi, Sanam
    Patel, Keyur P. P.
    Kanagal-Shamanna, Rashmi
    Yilmaz, Musa
    Masarova, Lucia
    Jabbour, Elias
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (10) : 1619 - 1626
  • [7] Monitoring T315I mutation in chronic myeloid leukemia by amplification refractory mutation system PCR
    Dima, Delia
    Trifa, Adrian P.
    Cucuianu, Andrei
    Popp, Radu A.
    Patiu, Mariana
    Petrov, Ljubomir
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2008, 13 (04): : 17 - 20
  • [8] Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation
    Ferri, Cristian A.
    Bianchini, Michele
    Bengio, Raquel M.
    Moiraghi, Elena B.
    Gonzalez, Mariana S.
    Noriega, Maria F.
    Larripa, Irene B.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (03) : 270 - 272
  • [9] T315I mutation with lymphoblasts in a newly diagnosed patient with chronic-phase chronic myeloid leukemia
    Kimura, Kenji
    Tsukamoto, Shokichi
    Takaishi, Koji
    Isshiki, Yusuke
    Kayamori, Kensuke
    Hino, Yutaro
    Ohshima-Hasegawa, Nagisa
    Mitsukawa, Shio
    Takeda, Yusuke
    Mimura, Naoya
    Takeuchi, Masahiro
    Ohwada, Chikako
    Iseki, Tohru
    Nakaseko, Chiaki
    Sakaida, Emiko
    LEUKEMIA & LYMPHOMA, 2019, 60 (06) : 1591 - 1594
  • [10] Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance
    Chahardouli, Bahram
    Zaker, Farhad
    Mousavi, Seied Asadollah
    Kazemi, Ahmad
    Ostadali, Mohammadreza
    Nadali, Fatemeh
    Rostami, Shahrbano
    Alimoghaddam, Kamran
    Ghavamzade, Ardeshir
    HEMATOLOGY, 2013, 18 (03) : 158 - 162
12345